EE200100631A - Amlodipiini ja atorvastatiini ühised eelravimid - Google Patents

Amlodipiini ja atorvastatiini ühised eelravimid

Info

Publication number
EE200100631A
EE200100631A EEP200100631A EEP200100631A EE200100631A EE 200100631 A EE200100631 A EE 200100631A EE P200100631 A EEP200100631 A EE P200100631A EE P200100631 A EEP200100631 A EE P200100631A EE 200100631 A EE200100631 A EE 200100631A
Authority
EE
Estonia
Prior art keywords
amlodipine
atorvastatin
common prodrugs
prodrugs
common
Prior art date
Application number
EEP200100631A
Other languages
English (en)
Estonian (et)
Inventor
Chang George
Seiichi Hamanaka Ernest
Lawrence Lamattina John
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200100631A publication Critical patent/EE200100631A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
EEP200100631A 1999-05-27 2000-03-20 Amlodipiini ja atorvastatiini ühised eelravimid EE200100631A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13660899P 1999-05-27 1999-05-27
PCT/IB2000/000313 WO2000073298A1 (fr) 1999-05-27 2000-03-20 Promedicaments communs d'amlodipine et d'atorvastatine

Publications (1)

Publication Number Publication Date
EE200100631A true EE200100631A (et) 2003-02-17

Family

ID=22473579

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100631A EE200100631A (et) 1999-05-27 2000-03-20 Amlodipiini ja atorvastatiini ühised eelravimid

Country Status (41)

Country Link
US (1) US6486182B1 (fr)
EP (1) EP1180102B9 (fr)
JP (1) JP2003500487A (fr)
KR (1) KR20020012247A (fr)
CN (1) CN1352640A (fr)
AP (1) AP2001002345A0 (fr)
AR (1) AR022344A1 (fr)
AT (1) ATE268764T1 (fr)
AU (1) AU3313900A (fr)
BG (1) BG106149A (fr)
BR (1) BR0011006A (fr)
CA (1) CA2375372C (fr)
CO (1) CO5170457A1 (fr)
CZ (1) CZ20014229A3 (fr)
DE (1) DE60011424T2 (fr)
DK (1) DK1180102T3 (fr)
DZ (1) DZ3048A1 (fr)
EA (1) EA200101130A1 (fr)
EE (1) EE200100631A (fr)
ES (1) ES2220426T3 (fr)
GT (1) GT200000078A (fr)
HK (1) HK1046282A1 (fr)
HN (1) HN2000000075A (fr)
HR (1) HRP20010856A2 (fr)
HU (1) HUP0201433A2 (fr)
IL (1) IL145947A0 (fr)
IS (1) IS6135A (fr)
MA (1) MA26736A1 (fr)
MX (1) MXPA01012125A (fr)
NO (1) NO20015756L (fr)
OA (1) OA11950A (fr)
PA (1) PA8495701A1 (fr)
PE (1) PE20010169A1 (fr)
PL (1) PL353483A1 (fr)
PT (1) PT1180102E (fr)
SK (1) SK16792001A3 (fr)
SV (1) SV2002000082A (fr)
TN (1) TNSN00113A1 (fr)
TR (1) TR200103391T2 (fr)
WO (1) WO2000073298A1 (fr)
ZA (1) ZA200109691B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
WO2002100347A2 (fr) 2001-06-11 2002-12-19 Xenoport, Inc. Promedicaments d'analogues de gaba, compositions et utilisations desdits promedicaments
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
EP1811986B1 (fr) 2004-11-04 2014-03-26 XenoPort, Inc. Formes posologiques orales a liberation prolongee d'un promedicament de la gabapentine
EP1909848A2 (fr) * 2005-08-01 2008-04-16 PSivida Inc. Composes inhibiteurs de l'enzyme de conversion de l'angiotensine- inhibiteurs de la hmgcoa reductase
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US8371336B2 (en) 2007-10-10 2013-02-12 Eagle Industry Co., Ltd. Accumulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
IS6135A (is) 2001-10-30
HN2000000075A (es) 2001-02-02
GT200000078A (es) 2001-11-16
AP2001002345A0 (en) 2001-12-31
MA26736A1 (fr) 2004-12-20
CN1352640A (zh) 2002-06-05
EP1180102B1 (fr) 2004-06-09
DZ3048A1 (fr) 2004-03-27
US6486182B1 (en) 2002-11-26
BR0011006A (pt) 2002-02-19
CO5170457A1 (es) 2002-06-27
CA2375372A1 (fr) 2000-12-07
AR022344A1 (es) 2002-09-04
EA200101130A1 (ru) 2002-04-25
SK16792001A3 (sk) 2003-03-04
EP1180102B9 (fr) 2005-03-02
WO2000073298A1 (fr) 2000-12-07
NO20015756L (no) 2002-01-24
PE20010169A1 (es) 2001-02-10
BG106149A (en) 2002-05-31
ZA200109691B (en) 2002-11-26
CZ20014229A3 (cs) 2003-01-15
HRP20010856A2 (en) 2002-12-31
NO20015756D0 (no) 2001-11-26
JP2003500487A (ja) 2003-01-07
HK1046282A1 (zh) 2003-01-03
PA8495701A1 (es) 2001-12-14
PT1180102E (pt) 2004-08-31
HUP0201433A2 (en) 2002-08-28
CA2375372C (fr) 2007-01-09
SV2002000082A (es) 2002-02-05
KR20020012247A (ko) 2002-02-15
TNSN00113A1 (fr) 2005-11-10
AU3313900A (en) 2000-12-18
EP1180102A1 (fr) 2002-02-20
DK1180102T3 (da) 2004-09-06
ES2220426T3 (es) 2004-12-16
IL145947A0 (en) 2002-07-25
PL353483A1 (en) 2003-11-17
TR200103391T2 (tr) 2002-04-22
OA11950A (en) 2006-04-13
MXPA01012125A (es) 2002-06-04
ATE268764T1 (de) 2004-06-15
DE60011424T2 (de) 2005-08-25
DE60011424D1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
EE200100632A (et) Amlodipiini ja atorvastatiini ühine sool
EE200100631A (et) Amlodipiini ja atorvastatiini ühised eelravimid
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
DK1491193T3 (da) Terapeutiske kombinationer omfattende amlodipin og atorvastatin
EE200100022A (et) Tiobensimidasooli derivaadid ja farmatseutiline kompositsioon
PT1411923E (pt) Composições farmacêuticas de amlodipina e atorvastatina
FI20002429L (fi) Päällepuhalluskuivatusyksikkö ja kuivatusosa
EE200200146A (et) Loteprednooli ja antihistamiinsete ainete uudne kombinatsioon
EE200400048A (et) Atorvastatiinkaltsiumi kristalsed vormid VI ja VII
AU2001283085A1 (en) Synergistic effect of amlodipine and atorvastatin
NO20015128L (no) Synergistiske virkninger av amlodipin og atorvastatin
SI1180102T1 (en) Mutual prodrugs of amlodipine and atorvastatin
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
GB0027410D0 (en) Mutual prodrug of amlodipine and atorvastatin
FI990281A7 (fi) Liitos erityisesti rakenne-elementtejä varten ja rakenne-elementti
NO20014454D0 (no) Konstruksjon og anvendelse av samme
FIU20000507U0 (fi) Clinikit DiagnoPacks ja Openkit-konsepti
ZA200108685B (en) Synergistic effects of amlodipine and atorvastatin.
FI4171U1 (fi) Hautakivi

Legal Events

Date Code Title Description
HD1A Correction of address